[A Case of Advanced XXXX with Irinotecan( @entity2600 )-Induced Delayed Emesis].

@entity1 @entity2600 @entity5 @entity391 @entity3
A64 -year-old @entity1 was referred to our hospital with a diagnosis of advanced @entity5 with @entity3 to the left supraclavicular lymph nodes and paraaortic lymph nodes. Alow anterior resection was performed because of the symptoms of ileus. Subsequently, chemotherapy consisting of XELOX with bevacizumab was initiated as the first-line regimen, over 6 courses. Asecond -line regimen of FOLFIRI with bevacizumab was selected due to multiple lung @entity3 and the progression to both left supraclavicular and paraaortic lymph nodes. During the first 3 courses, the @entity1 had no harmful side effects. Although the @entity1 received adequate prophylactic antiemetic therapy and supportive treatment, grade 4 delayed @entity391 induced by irinotecan( @entity2600 )occurred at 7 days after the fourth course of FOLFIRI chemotherapy. The @entity1 was given total parenteral nutrition, after which she recovered substantially from the @entity391 . Delayed @entity391 is occasionally seen with irinotecan therapy and can be efficiently managed with adequate prophylactic antiemetic therapy. However, delayed @entity391 occurring one week after administration is rarely observed. Delayed @entity391 and subsequent therapy affect the quality of life(QOL)of the @entity1 and subsequent therapy therefore, adequate attention and prompt management are required for delayed @entity391 .
